S3-Leitlinie Prostatakarzinom - AWMF

9. Literatur
160. Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, Bush DA, Lunt M, Spiegel
DY, Skowronski R, Jabola BR, Rossi CJ. Randomized trial comparing conventional-dose with
high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: longterm
results from proton radiation oncology group/american college of radiology 95-09.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1106-11. http://www.ncbi.nlm.nih.gov/pubmed/20124169
161. Kuban DA, Levy LB, Cheung MR, Lee AK, Choi S, Frank S, Pollack A. Long-term failure
patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of
disease? Int J Radiat Oncol Biol Phys 2011;79(5):1310-7.
http://www.ncbi.nlm.nih.gov/pubmed/20493642
162. Peeters ST, Lebesque JV, Heemsbergen WD, van Putten WL, Slot A, Dielwart MF, Koper PC.
Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate
cancer. Int J Radiat Oncol Biol Phys 2006;64(4):1151-61.
http://www.ncbi.nlm.nih.gov/pubmed/16414208
163. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ, Jr., Miller DW, Adams JA, Shipley WU.
Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically
localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA
2005;294(10):1233-9. http://www.ncbi.nlm.nih.gov/pubmed/16160131
164. Zapatero A, Valcarcel F, Calvo FA, Algas R, Bejar A, Maldonado J, Villa S. Risk-adapted
androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate
cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen
deprivation? A GICOR study. J Clin Oncol 2005;23(27):6561-8.
http://www.ncbi.nlm.nih.gov/pubmed/16170164
165. Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses in localized
prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat
Oncol Biol Phys 2009;74(5):1405-18. http://www.ncbi.nlm.nih.gov/pubmed/19616743
166. Al-Mamgani A, Heemsbergen WD, Levendag PC, Lebesque JV. Subgroup analysis of patients
with localized prostate cancer treated within the Dutch-randomized dose escalation trial.
Radiother Oncol 2010;96(1):13-8. http://www.ncbi.nlm.nih.gov/pubmed/20227123
167. Al-Mamgani A, van Putten WL, van der Wielen GJ, Levendag PC, Incrocci L. Dose Escalation
and Quality of Life in Patients With Localized Prostate Cancer Treated With Radiotherapy:
Long-Term Results of the Dutch Randomized Dose-Escalation Trial (CKTO 96-10 Trial). Int J
Radiat Oncol Biol Phys 2011;79(4):1004-12.
http://www.ncbi.nlm.nih.gov/pubmed/20421153
168. Beckendorf V, Guerif S, Le PE, Cosset JM, Lefloch O, Chauvet B, Salem N, Chapet O, Bourdin
S, Bachaud JM, Maingon P, Lagrange JL, Malissard L, Simon JM, Pommier P, Hay MH, Dubray
B, Luporsi E, Bey P. The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate
cancer: feasibility and acute toxicity. Int J Radiat Oncol Biol Phys 2004;60(4):1056-65.
http://www.ncbi.nlm.nih.gov/pubmed/15519775
169. Denham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, Atkinson C, North J,
Christie D, Spry NA, Tai KH, Wynne C, D'Este C. Short-term neoadjuvant androgen
deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the
TROG 96.01 randomised trial. Lancet Oncol 2011;12(5):451-9.
http://www.ncbi.nlm.nih.gov/pubmed/21440505
170. Denham JW, Steigler A, Lamb DS, Joseph D, Mameghan H, Turner S, Matthews J, Franklin I,
Atkinson C, North J, Poulsen M, Christie D, Spry NA, Tai KH, Wynne C, Duchesne G, Kovacev
O, D'Este C. Short-term androgen deprivation and radiotherapy for locally advanced
prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01
randomised controlled trial. Lancet Oncol 2005;6(11):841-50.
http://www.ncbi.nlm.nih.gov/pubmed/16257791
© Leitlinienprogramm Onkologie | S3-Leitlinie Prostatakarzinom | Version 2.0, 1. Aktualisierung 2011